All In Biotech

Drug Trial Radar · NCT00925275

Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors

A Phase I, Multi-Center, Open-Label, Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors Who Have Failed Standard Therapy or for Whom No Standard Therapy Exists

Last checked: Nov 19, 2026Latest source record: May 4, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

9

Planned (sponsor's estimate)

Start

Jun 2009

Primary completion

Feb 2010

Study completion Feb 2010

Sponsor

Lead sponsor
Cellectar, IncIndustry
Sponsor type
Industry
First posted
Jun 22, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Basic science
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to investigate the safety, biodistribution, radiation dosimetry and pharmacokinetics of I-131-CLR1404.

Conditions

  • Solid Tumors

Interventions

  • I-131-CLR1404Drug

    Single intravenous injection of 10 millicuries of I-131-CLR1404 given on Day 0

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Calculate whole body and organ radiation dosimetry of I-131-CLR1404 to determine the millicurie dose which is expected to deliver 35-40 centigray of radiation to bone marrowTime frame: 42 days

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California

  • Georgetown University, Lombardi Cancer Center

    Washington D.C., District of Columbia

  • Johns Hopkins University School of Medicine

    Baltimore, Maryland

  • Duke University Medical Center

    Durham, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.